MEDNAX Inc (NYSE:MD) Director Md Pascal J. Goldschmidt sold 3,300 shares of the company’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $30.40, for a total value of $100,320.00. Following the transaction, the director now owns 20,821 shares of the company’s stock, valued at $632,958.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of NYSE MD traded down $0.57 during trading hours on Friday, reaching $30.04. The stock had a trading volume of 1,438,256 shares, compared to its average volume of 1,206,532. The company has a current ratio of 1.31, a quick ratio of 1.31 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $2.67 billion, a price-to-earnings ratio of 8.56, a PEG ratio of 1.05 and a beta of 0.61. MEDNAX Inc has a twelve month low of $29.34 and a twelve month high of $57.61.
MEDNAX (NYSE:MD) last issued its earnings results on Thursday, February 7th. The company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.09. The business had revenue of $932.70 million during the quarter, compared to analyst estimates of $910.08 million. MEDNAX had a return on equity of 10.35% and a net margin of 7.37%. MEDNAX’s revenue was up 2.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.87 earnings per share. On average, research analysts anticipate that MEDNAX Inc will post 3.43 earnings per share for the current fiscal year.
MD has been the subject of a number of research analyst reports. Citigroup upgraded MEDNAX from a “neutral” rating to a “buy” rating and set a $34.88 price target for the company in a report on Monday, January 14th. They noted that the move was a valuation call. UBS Group initiated coverage on MEDNAX in a report on Friday, November 16th. They set a “sell” rating and a $37.00 price target for the company. Deutsche Bank initiated coverage on MEDNAX in a report on Thursday, January 3rd. They set a “hold” rating and a $34.00 price target for the company. Credit Suisse Group cut their price target on MEDNAX from $44.00 to $42.00 and set an “outperform” rating for the company in a report on Wednesday, February 13th. Finally, Mizuho set a $36.00 price target on MEDNAX and gave the stock a “hold” rating in a report on Friday, February 8th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company’s stock. MEDNAX has a consensus rating of “Hold” and an average target price of $42.90.
MEDNAX Company Profile
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.
Recommended Story: Conference Calls and Individual Investors
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.